x
Filter:
Filters applied
- JLR Patient-Oriented and Epidemiological Research
- cardiovascular diseaseRemove cardiovascular disease filter
- Journal of Lipid ResearchRemove Journal of Lipid Research filter
Publication Date
Please choose a date range between 2016 and 2021.
Author
- Ala-Korpela, Mika1
- Alexander, Veronica J1
- Benčič, Aleksander1
- Billings, Frederic T IV1
- Boehnke, Michael1
- Boeing, Heiner1
- Bogensberger, Berit1
- Burant, Charles F1
- Choi, Yun-Seok1
- Digenio, Andres1
- Djousse, Luc1
- Fretts, Amanda M1
- Hoffmann, Georg1
- Hoofnagle, Andrew N1
- Howard, Barbara V1
- Jackson, Anne U1
- Jensen, Paul N1
- Kangas, Antti J1
- Kim, Daniel Seung1
- King, Irena B1
- Knüppel, Sven1
- Kon, Valentina1
- Kuusisto, Johanna1
- Laakso, Markku1
- Lee, Sang-Rok1
Keyword
- epidemiology2
- antisense oligonucleotides1
- apolipoprotein B-1001
- apolipoprotein C-III1
- C-reactive protein1
- Cardiovascular Health Study1
- Cer1
- ceramide1
- ceramides1
- CHD1
- cholesterol1
- CHS1
- cohort study1
- coronary heart disease1
- Cox proportional hazards1
- CRP1
- CVD1
- diabetes1
- eicosanoids1
- elderly1
- evidence synthesis1
- HDL function1
- National Heart, Lung, and Blood Institute1
- NHLBI1
JLR Patient-Oriented and Epidemiological Research
5 Results
- Patient-oriented and Epidemiological ResearchOpen Access
Perioperative high density lipoproteins, oxidative stress, and kidney injury after cardiac surgery
Journal of Lipid ResearchVol. 62100024Published online: January 13, 2021- Loren E. Smith
- Derek K. Smith
- Patricia G. Yancey
- Valentina Kon
- Alan T. Remaley
- Frederic T. Billings IV
- and others
Cited in Scopus: 0Oxidative stress promotes acute kidney injury (AKI). Higher HDL cholesterol concentrations are associated with less AKI. To test the hypothesis that HDL antioxidant activity is associated with AKI after cardiac surgery, we quantified HDL particle (HDL-P) size and number, paraoxonase-1 (PON-1) activity, and isofuran concentrations in 75 patients who developed AKI and 75 matched control patients. Higher preoperative HDL-P was associated with less AKI (OR: 0.80; 95% CI, 0.71–0.91; P = 0.001), higher PON-1 activity ( P < 0.001), and lower plasma concentrations of isofurans immediately after surgery (P = 0.02). - Patient-oriented and Epidemiological ResearchOpen Access
Plasma ceramides containing saturated fatty acids are associated with risk of type 2 diabetes
Journal of Lipid ResearchVol. 62100119Published online: September 20, 2021- Amanda M. Fretts
- Paul N. Jensen
- Andrew N. Hoofnagle
- Barbara McKnight
- Barbara V. Howard
- Jason Umans
- and others
Cited in Scopus: 0Recent studies suggest that the type of saturated fatty acid bound to sphingolipids influences the biological activity of those sphingolipids. However, it is unknown whether associations of sphingolipids with diabetes may differ by the identity of bound lipid species. Here, we investigated associations of 15 ceramide (Cer) and SM species (i.e., all sphingolipids, measured with coefficient of variation less than 20%) with incident type 2 diabetes in the Cardiovascular Health Study (n = 3,645), a large cohort study of cardiovascular disease among elderly adults who were followed from 1989 to 2015. - Patient-Oriented and Epidemiological ResearchOpen Access
Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis
Journal of Lipid ResearchVol. 59Issue 9p1771–1782Published online: July 13, 2018- Lukas Schwingshackl
- Berit Bogensberger
- Aleksander Benčič
- Sven Knüppel
- Heiner Boeing
- Georg Hoffmann
Cited in Scopus: 68The aim of this network meta-analysis (NMA) is to compare the effects of different oils/solid fats on blood lipids. Literature searches were performed until March 2018. Inclusion criteria were as follows: i) randomized trial (≥3 weeks study length) comparing at least two of the following oils/solid fats: safflower, sunflower, rapeseed, hempseed, flaxseed, corn, olive, soybean, palm, and coconut oil, and lard, beef-fat, and butter; ii) outcomes LDL-cholesterol (LDL-C), total cholesterol (TC), HDL-cholesterol (HDL-C), and triacylglycerols (TGs). - Patient-Oriented and Epidemiological ResearchOpen Access
Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns
Journal of Lipid ResearchVol. 58Issue 7p1471–1481Published online: May 24, 2017- Daniel Seung Kim
- Anne U. Jackson
- Yatong K. Li
- Heather M. Stringham
- Johanna Kuusisto
- Antti J. Kangas
- and others
Cited in Scopus: 39A glutamate-to-lysine variant (rs58542926-T) in transmembrane 6 superfamily member 2 (TM6SF2) is associated with increased fatty liver disease and diabetes in conjunction with decreased cardiovascular disease risk. To identify mediators of the effects of TM6SF2, we tested for associations between rs58542926-T and serum lipoprotein/metabolite measures in cross-sectional data from nondiabetic statin-naïve participants. We identified independent associations between rs58542926-T and apoB-100 particles (β = −0.057 g/l, P = 1.99 × 10−14) and tyrosine levels (β = 0.0020 mmol/l, P = 1.10 × 10−8), controlling for potential confounders, in 6,929 Finnish men. - Patient-Oriented and Epidemiological ResearchOpen Access
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
Journal of Lipid ResearchVol. 57Issue 4p706–713Published online: January 4, 2016- Xiaohong Yang
- Sang-Rok Lee
- Yun-Seok Choi
- Veronica J. Alexander
- Andres Digenio
- Qingqing Yang
- and others
Cited in Scopus: 76Elevated apoC-III levels predict increased cardiovascular risk when present on LDL and HDL particles. We developed novel high-throughput chemiluminescent ELISAs that capture apoB, lipoprotein (a) [Lp(a)], and apoA-I in plasma and then detect apoC-III on these individual lipoproteins as apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI complexes, respectively. We assessed the effects on these complexes of placebo or 100–300 mg volanesorsen, a generation 2.0+ antisense drug that targets apoC3 mRNA in patients with hypertriglyceridemia, including familial chylomicronemia syndrome (n = 3), volanesorsen monotherapy (n = 51), and as add-on to fibrate (n = 26), treated for 85 days and followed for 176 days.